Skip to main content

Anthrax Antimicrobial One Goal of Paradigm Genetics, VDDI Collaboration

NEW YORK, Feb. 26 - Paradigm Genetics and VDDI Pharmaceuticals will research and develop novel antibiotics for certain bacteria that may be used as bioterror agents, the companies said on Tuesday.

Terms of the deal call for Paradigm to supply its MetaVantage platform. VDDI, meanwhile, will provide samples of a new class of antimicrobials recently discovered at the University of Alabama.

VDDI acquired the rights to the antimicrobial compounds, which researchers at the school claim target an important enzyme responsible for keeping alive certain microbes, in this case gram-positive bugs like Anthrax.

The agreement also gives Paradigm the option to co-develop with VDDI certain compounds for antibiotic and anti-fungal applications for applications in human health and agrochemistry.

Financial details of the collaboration were not disclosed.

This deal was originally funded with the help of a $6 million Defense Advanced Research Projects Agency grant to the UAB Center for Biophysical Sciences and Engineering, VDDI said. Next month, the US Department of Defense is set to award VDDI a multi-year contract worth $23 million to research and develop antibiotics that treat Anthrax.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.